{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "single-center, double-blind, randomized, parallel-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "102 patients undergoing elective thoracoscopic surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to thoracic paravertebral block with LB (6.67 mg/mL) or ropivacaine hydrochloride (RH; 0.33%)"
      },
      "Objective": {
        "score": 1,
        "evidence": "we investigated the effects of LB in multimodal analgesia after thoracic surgery with paravertebral block"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was opioid consumption within 72 h postoperatively"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "102 patients undergoing elective thoracoscopic surgery were randomized 1:1"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "One patient was excluded due to block failure, leaving 101 patients"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "LB significantly reduced 72-h opioid consumption compared to RH (difference = \u2013181.4 mg; 95% CI: \u2013232.8, \u2013130.0 mg; P < 0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "adverse events"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Chinese Clinical Trials Registry Platform (chictr.org.cn): ChiCTR2400091217"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}